Values First Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Values First Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,609	Closed	-$215K	–	181
2023 Q2	$215K	Buy	5,609 +3,219	+135%	+$82.7K	0.13%	143
2023 Q1	$55.3K	Buy	+2,390	New	+$57K	0.04%	186

Values First Advisors's KDNY Position: Q3 2023 in Review

Values First Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 5,609 shares — an estimated $215K sold.

Values First Advisors first reported a position in KDNY in Q1 2023 and held it in 2 quarters. The position peaked at $215K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Values First Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Values First Advisors sold 5,609 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $215K.
Values First Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
Values First Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $215K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Values First Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.